John Greene Buys 7,000 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) Director John Greene purchased 7,000 shares of the firm’s stock in a transaction dated Wednesday, February 26th. The shares were bought at an average cost of $44.85 per share, for a total transaction of $313,950.00. Following the completion of the purchase, the director now directly owns 7,000 shares of the company’s stock, valued at $313,950. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

CRISPR Therapeutics Stock Performance

Shares of CRSP opened at $43.92 on Friday. The stock has a 50 day simple moving average of $42.49 and a 200 day simple moving average of $45.95. CRISPR Therapeutics AG has a 52-week low of $36.52 and a 52-week high of $89.88. The firm has a market capitalization of $3.77 billion, a PE ratio of -10.05 and a beta of 1.67.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. Equities research analysts predict that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Hedge Funds Weigh In On CRISPR Therapeutics

A number of large investors have recently added to or reduced their stakes in CRSP. International Assets Investment Management LLC acquired a new position in shares of CRISPR Therapeutics during the third quarter worth about $1,825,000. Mirae Asset Global Investments Co. Ltd. boosted its position in CRISPR Therapeutics by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,080 shares of the company’s stock worth $146,000 after acquiring an additional 545 shares during the last quarter. Pinnacle Associates Ltd. bought a new position in shares of CRISPR Therapeutics during the 3rd quarter worth approximately $188,000. HM Payson & Co. raised its holdings in shares of CRISPR Therapeutics by 115.7% in the third quarter. HM Payson & Co. now owns 2,330 shares of the company’s stock valued at $109,000 after purchasing an additional 1,250 shares during the last quarter. Finally, Congress Asset Management Co. grew its position in CRISPR Therapeutics by 2.8% in the third quarter. Congress Asset Management Co. now owns 65,768 shares of the company’s stock valued at $3,090,000 after purchasing an additional 1,788 shares in the last quarter. Institutional investors own 69.20% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on CRSP shares. JMP Securities reissued a “market outperform” rating and issued a $86.00 target price on shares of CRISPR Therapeutics in a research note on Thursday, February 13th. Morgan Stanley lifted their price objective on CRISPR Therapeutics from $30.00 to $32.00 and gave the stock an “underweight” rating in a research report on Friday, February 14th. Barclays upped their target price on shares of CRISPR Therapeutics from $55.00 to $56.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 12th. Needham & Company LLC reiterated a “buy” rating and set a $84.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday, February 12th. Finally, The Goldman Sachs Group cut their price objective on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating on the stock in a report on Thursday, February 13th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $74.40.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.